# Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/malignancy-risk-with-tofacitinib-versus-tnf-inhibitors-in-rheumatoid-arthritis/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jeffrey R. Curtis,Kunihiro Yamaoka,Yi‐Hsing Chen,Deepak L. Bhatt,Levent M Gunay,Naonobu Sugiyama,Carol A. Connell,Cunshan Wang,Joseph Wu,Sujatha Menon,Ivana Vranić,Juan J. Gómez‐Reino |
| Citations | 164 |
| DOI | 10.1136/ard-2022-222543 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://ard.bmj.com/content/annrheumdis/82/3/331.full.pdf |
| OpenAlex ID | https://openalex.org/W4311621329 |
| PMID | 36600185 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Yi‐Hsing Chen](https://scholariq.org/researchers/yi-hsing-chen/)

## Paper journal

- [Annals of the Rheumatic Diseases](https://scholariq.org/journals/annals-of-the-rheumatic-diseases/)

## Paper primary topic

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)

## Paper topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.